Novel Diagnostics for Early Lyme Disease
common.study.values.description
“Novel Diagnostics for Early Lyme Disease”
There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses. Definitive diagnosis is based on serum-based tests that have fundamental limitations: 1) current tests cannot detect early infections so patients do not receive antibiotic therapy until the infection has progressed, and 2) there is no way to measure if antibiotic therapy has been successful. MicroB-plex will address these two unmet clinical needs by introducing a novel, blood-based diagnostic method that will enable clinicians to diagnose infections earlier and to monitor the success of their interventions.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


Diagnostic Test - MicroB-plex Lyme Immunoassay
Subject's blood and clinical data are collected to develop a diagnostic immunoassay
participant.views.study.view.additional
participant.views.study.view.scientific-title
Novel Diagnostics for Early Lyme Disease
common.study.values.clinical-trial-id
NCT03963635
participant.views.study.view.id
azpzqd